1. Glipizide, a new oral antidiabetic agent (report of a controlled clinical study in Sweden)
- Author
-
A. Johannessen and S. E. Fagerberg
- Subjects
Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,Time Factors ,Endocrinology, Diabetes and Metabolism ,Administration, Oral ,Newly diagnosed ,Pharmacology ,Placebo ,Diabetes treatment ,Placebos ,Clinical study ,Cyclohexanes ,Glycosuria ,Diabetes mellitus ,Internal medicine ,Diet, Diabetic ,Diabetes Mellitus ,Internal Medicine ,medicine ,Humans ,Hypoglycemic Agents ,Potency ,Aged ,Sweden ,Clinical Trials as Topic ,business.industry ,Body Weight ,Sodium ,Human physiology ,Middle Aged ,medicine.disease ,Cholesterol ,Sulfonylurea Compounds ,Pyrazines ,Potassium ,Drug Evaluation ,Female ,business ,hormones, hormone substitutes, and hormone antagonists ,Glipizide ,medicine.drug - Abstract
Twelve newly diagnosed and eleven previously unsuccessfully treated diabetics were included in a strictly controlled cross-over trial comparing the efficacy of glipizide with that of a placebo or the previous orally administered antidiabetic drug. All newly diagnosed diabetics responded to glipizide and in eleven of them (91%), the control of the glycaemia was “excellent” or “good”. In the cases with severe diabetes, glipizide achieved on an average a better control of the glycaemia due to meals than that produced by the previous therapy. — Neither hypoglycaemia nor side-effects have been observed. We therefore conclude that glipizide is an effective and safe high potency oral sulphonylurea.
- Published
- 1973
- Full Text
- View/download PDF